ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 128 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 4.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $8,540,000 | +9.5% | 119,972 | -7.6% | 3.54% | -53.2% |
| Q3 2019 | $7,802,000 | +41.2% | 129,867 | +98.3% | 7.57% | +99.0% |
| Q2 2019 | $5,526,000 | -4.9% | 65,484 | +7.6% | 3.80% | +13.9% |
| Q1 2019 | $5,811,000 | -54.7% | 60,840 | -72.1% | 3.34% | -56.5% |
| Q4 2017 | $12,818,000 | -29.8% | 218,434 | -44.0% | 7.68% | -28.6% |
| Q3 2017 | $18,252,000 | +3.0% | 390,000 | -20.8% | 10.76% | +12.5% |
| Q2 2017 | $17,712,000 | +210.7% | 492,265 | +165.9% | 9.56% | +197.7% |
| Q1 2017 | $5,701,000 | -26.6% | 185,099 | -20.2% | 3.21% | -30.6% |
| Q4 2016 | $7,769,000 | +230.7% | 231,913 | +226.0% | 4.63% | +68.1% |
| Q4 2015 | $2,349,000 | – | 71,147 | – | 2.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
| Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
| ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
| Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
| Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
| Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
| Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
| Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |